Pharmacogenomics of human uridine diphospho-glucuronosyltransferases (UGTs) and clinical implications

Authors: Guillemette, ChantalLévesque, ÉricRouleau, Michèle
Abstract: Glucuronidation, mediated by UDP-glucuronosyltransferase enzymes (UGTs), is a major phase II biotransformation pathway and, complementary to phase I metabolism and membrane transport, one of the most important cellular defense mechanism responsible for the inactivation of therapeutic drugs, other xenobiotics and numerous endogenous molecules. Individual variability in UGT enzymatic pathways is significant and may have profound pharmacological and toxicological implications. Several genetic and genomic processes are underlying this variability and are discussed in the context of drug metabolism and diseases such as cancer.
Document Type: Article de recherche
Issue Date: 12 June 2014
Open Access Date: 31 August 2016
Document version: AM
Permalink: http://hdl.handle.net/20.500.11794/9528
This document was published in: Clinical Pharmacology & Therapeutics (2014)
https://doi.org/10.1038/clpt.2014.126
Wiley
Alternative version: 10.1038/clpt.2014.126
24922307
Collection:Articles publiés dans des revues avec comité de lecture

Files in this item:
SizeFormat 
Guillemette_CPT_manuscriptREVISED-FINALfordepot.pdf1.49 MBAdobe PDFView/Open
All documents in CorpusUL are protected by Copyright Act of Canada.